Status:

COMPLETED

Defibrotide TMA Prophylaxis Pilot Trial

Lead Sponsor:

University of California, San Francisco

Conditions:

Thrombotic Microangiopathies

Eligibility:

All Genders

Up to 30 years

Phase:

PHASE2

Brief Summary

Thrombotic microangiopathy (TMA) is a common complication in the stem cell transplant population. Certain populations within the hematopoietic stem cell transplant (HSCT) population are at a higher ri...

Detailed Description

This is an open-label, single arm pilot study of defibrotide given as prophylaxis to patients receiving a conditioned stem cell transplant for the purpose of preventing post-transplant microangiopathy...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age 0-30 years of age
  • Life expectancy \> 6 months
  • Eastern Cooperative Oncology Group or Karnofsky Performance Status \>40
  • Meets minimum organ function requirements per institutional standard of care guiding clearance for autologous or allogeneic stem cell transplantation.
  • Patients must meet TMA High-Risk criteria 5A or 5B below:
  • 5A. Patients undergoing tandem autologous transplant with thiotepa in one or more of the conditioning regimens
  • OR:
  • 5B. . Patients with at least 3 of the following characteristics:
  • \>10 years of age
  • Non-Caucasian race/ Hispanic ethnicity
  • Undergoing haploidentical transplant
  • Minor ABO blood group mismatch
  • Exclusion Criteria:
  • Age \>30 years
  • Life expectancy \< 6 months
  • Known bleeding diathesis or bleeding risk deemed by the treating physician to be a contraindication to administration of anticoagulants.
  • Known hypersensitivity reaction to defibrotide
  • Any patient not meeting TMA High-Risk criteria
  • Pregnant women are excluded from this study because they will be receiving teratogenic therapy as part of the stem cell transplant.

Exclusion

    Key Trial Info

    Start Date :

    May 1 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 31 2020

    Estimated Enrollment :

    25 Patients enrolled

    Trial Details

    Trial ID

    NCT03384693

    Start Date

    May 1 2018

    End Date

    July 31 2020

    Last Update

    September 16 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Benioff Children's Hospital at UCSF Medical Center

    San Francisco, California, United States, 94143